Cibus (CBUS)
NASDAQ:CBUS
CBUS Stock Chart & Stats
$1.42
-$0.23(-7.99%)
At close: 4:00 PM EST
$1.42
-$0.23(-7.99%)
Day’s Range― - ―
52-Week Range$1.09 - $4.19
Previous CloseN/A
Volume64.89K
Average Volume (3M)154.04K
Market Cap
$110.45M
Enterprise Value$322.63M
Total Cash (Recent Filing)$9.92M
Total Debt (Recent Filing)$267.96M
Price to Earnings (P/E)―
Beta2.83
Next Earnings
May 07, 2026EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.59
Shares Outstanding76,172,870
10 Day Avg. Volume164,630
30 Day Avg. Volume154,044
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)36.47
Price to Sales (P/S)218.79
P/FCF Ratio-15.56
Enterprise Value/Market Cap2.92
Enterprise Value/Revenue88.66
Enterprise Value/Gross Profit370.84
Enterprise Value/Ebitda-5.24
Forecast
1Y Price Target
$14.67Price Target Upside933.10% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.93
Revenue Forecast (FY)$8.02M
Bulls Say, Bears Say
Bulls Say
Cost And Liquidity PositionCompanywide cost reductions combined with a capital raise strengthen liquidity and back planned operating needs and capital expenditures, improving the cash runway for commercialization efforts.
Product Market TractionEarly commercial orders for sustainable ingredients and initial customer payments for bio-based fragrances indicate growing market acceptance and a pathway to diversified revenue streams.
Regulatory ProgressRegulatory advances in the European Union and favorable rulings from U.S. regulators support broader commercial acceptance of gene-edited crops, lowering barriers for trait insertion and biofragrance commercialization.
Bears Say
Breakeven Dependency RiskFree cash flow breakeven depends on successful commercialization of rice royalties, biofragrances, and bespoke research services, creating execution-sensitive pressure on cash generation.
Revenue Concentration RiskHeavy reliance on a limited set of rice seed customers and regional royalty agreements concentrates revenue risk and could delay meaningful royalty income if adoption is slower than expected.
Scale-up And Partner Funding UncertaintyConversion of pilot runs and trials into partner-funded projects carries execution risk, and failure to scale these initiatives would slow revenue growth from herbicide-tolerant crops and biofragrance lines.
Cibus News
CBUS FAQ
What was Cibus’s price range in the past 12 months?
Cibus lowest stock price was $1.09 and its highest was $4.19 in the past 12 months.
What is Cibus’s market cap?
Cibus’s market cap is $110.45M.
When is Cibus’s upcoming earnings report date?
Cibus’s upcoming earnings report date is May 07, 2026 which is in 22 days.
How were Cibus’s earnings last quarter?
Cibus released its earnings results on Mar 17, 2026. The company reported -$0.59 earnings per share for the quarter, missing the consensus estimate of -$0.352 by -$0.238.
Is Cibus overvalued?
According to Wall Street analysts Cibus’s price is currently Undervalued.
Does Cibus pay dividends?
Cibus does not currently pay dividends.
What is Cibus’s EPS estimate?
Cibus’s EPS estimate is -0.26.
How many shares outstanding does Cibus have?
Cibus has 76,172,870 shares outstanding.
What happened to Cibus’s price movement after its last earnings report?
Cibus reported an EPS of -$0.59 in its last earnings report, missing expectations of -$0.352. Following the earnings report the stock price went down -24.728%.
Which hedge fund is a major shareholder of Cibus?
Currently, no hedge funds are holding shares in CBUS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cibus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$14.67 (933.10% Upside)
$14.67 (933.10% Upside)
Hedge Fund Trend
Decreased
By 22.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.7%
Last 30 Days ▲ 9.3%
Last 30 Days ▲ 9.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-38.92%
12-Months-Change
Fundamentals
Return on Equity
-236.85%
Trailing 12-Months
Asset Growth
-12.86%
Trailing 12-Months
Company Description
Cibus
Cibus, Inc., a agricultural technology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases. The company is based in San Diego, California.
CBUS Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed substantial positive progress on technology performance, regulatory milestones, customer engagements, and near-term commercialization plans (especially for rice and sustainable ingredients). Management also executed meaningful cost reductions and secured a $22.3M financing to extend runway. Major challenges remain: the company is still loss-making with a Q4 net loss widened ~23.6%, royalty interest expense is significant, collaboration revenue timing weighed on results, and cash runway extends only into late 2026 absent further revenue or financing. Overall, the call emphasized execution and upcoming catalysts (EU plenary vote, Interox definitive agreement, Latin America field results) that support momentum but also highlighted the need to convert progress into cash flow in the near term.View all CBUS earnings summariesCBUS Stock 12 Month Forecast
Average Price Target
$14.67
▲(933.10% Upside)
Technical Analysis
Ownership Overview
30.02% Insiders
7.68% Mutual Funds
2.79% Other Institutional Investors
56.72% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---